U.S. Insomnia Market by OTC Treatment (Melatonin, Antihistamine, Valerian Root), Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Non-Benzodiazepines, Benzodiazepines, Orexin Antagonist)- 2021 to 2026

$3,850.00$5,850.00

Published on: March 23, 2021
Clear
SKU: GMS-3024 Category:

OVERVIEW

Amid the COVID-19 pandemic, The U.S. insomnia treatment market is expected to cross USD 7.12 billion by 2026, rising from 2021 to 2026 at a CAGR of 3.9%. This rise can be due to the advent of new medications to treat insomnia and government funding to reduce the increasing cost of insomnia. Nonetheless, due to the decline in the sales of branded drugs and they may acceptance of generics due to their low cost and equivalent effectiveness as opposed to branded products, market growth could be hampered. The report will also account for COVID-19 as a key market contributor.

U.S. Insomnia Market by OTC Treatment (Melatonin, Antihistamine, Valerian Root), Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Non-Benzodiazepines, Benzodiazepines, Orexin Antagonist)- 2021 to 2026 1

U.S. Insomnia Market by OTC Treatment (Melatonin, Antihistamine, Valerian Root), Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Non-Benzodiazepines, Benzodiazepines, Orexin Antagonist)- 2021 to 2026 2

U.S. Insomnia Market by OTC Treatment (Melatonin, Antihistamine, Valerian Root), Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Non-Benzodiazepines, Benzodiazepines, Orexin Antagonist)- 2021 to 2026 3

U.S. Insomnia Market by OTC Treatment (Melatonin, Antihistamine, Valerian Root), Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Non-Benzodiazepines, Benzodiazepines, Orexin Antagonist)- 2021 to 2026 4

U.S. Insomnia Market by OTC Treatment (Melatonin, Antihistamine, Valerian Root), Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Non-Benzodiazepines, Benzodiazepines, Orexin Antagonist)- 2021 to 2026 5

U.S. Insomnia Market by OTC Treatment (Melatonin, Antihistamine, Valerian Root), Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Non-Benzodiazepines, Benzodiazepines, Orexin Antagonist)- 2021 to 2026 6

U.S. Insomnia Market by OTC Treatment (Melatonin, Antihistamine, Valerian Root), Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Non-Benzodiazepines, Benzodiazepines, Orexin Antagonist)- 2021 to 2026 7

U.S. Insomnia Market by OTC Treatment (Melatonin, Antihistamine, Valerian Root), Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Non-Benzodiazepines, Benzodiazepines, Orexin Antagonist)- 2021 to 2026 8

TABLE OF CONTENT

1 U.S. Insomnia Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 U.S. Insomnia Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 U.S. Insomnia Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 U.S. Insomnia Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 U.S. Insomnia Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 U.S. Insomnia Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 U.S. Insomnia Market – By Treatment (Market Size – & million/billion)
8.1 Pharmacological Treatments
8.2 Non-pharmacological Treatments

9 U.S. Insomnia Market – By Pharmacological Treatment
9.1 Prescription Sleep Aids
9.2 Over-the-Counter Sleep Aids

10 U.S. Insomnia Market – By Non-pharmacological Treatment
10.1 Cognitive Behavioral Therapy for Insomnia (CBTI)
10.2 Hypnotherapy
10.3 Other

11 U.S. Insomnia Market – By Geography (Market Size – & million/billion)
11.1 Introduction
11.1.1 US
11.1.2 Canada
11.1.3 Mexico

12 U.S. Insomnia Market – Entropy
12.1 New product launches
12.2 M&A’s, collaborations, JVs and partnerships

13 U.S. Insomnia Market Company Profile (Key Players)
13.1 Market Share, Company Revenue, Products, M&A, Developments
13.2 Merck & Co., Inc.
13.3 Eisai Co., Ltd.
13.4 Meda Consumer Healthcare, Inc
13.5 Takeda Pharmaceuticals Company Ltd.
13.6 Pernix Therapeutics
13.7 Purdue Pharmaceuticals L.P.
13.8 Sanofi
13.9 Vanda Pharmaceuticals
13.10 Pfizer Inc.
13.11 Company 10
13.12 Company 11 & more

14 U.S. Insomnia Market – Appendix
14.1 Sources
14.2 Abbreviations